At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 70 enrolled
Drug / intervention
Phentermine 37.5 Mg +2 moredrug
Likely dose
Phentermine 37.5 Mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits
In Brief
A Phase 4 clinical trial evaluating Phentermine 37.5 Mg, Dietary program, and 1 other intervention for Obesity. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study will study the effects associated with the prescription of phentermine in a virtual setting, comparing with prescription of phentermine via a standard face-to-face visit for patients with obesity or overweight.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartJan 2021
Primary CompletionAug 2021
Study CompletionSep 2022
TodayJul 2026
First PostedNov 4, 2020
Enrollment StartJan 1, 2021
Primary CompletionAug 27, 2021
Study CompletionSep 29, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.7 years ago
Interventions
Phentermine 37.5 Mgdrug
Patients will receive 37.5 mg of phentermine daily for a 12 week duration
Dietary programbehavioral
Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
Exercise programbehavioral
Patients will be provided with a personalized exercise program